# MAR 2 5 2014

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

# 510(k) Summary

# 510(k) number:

# K133673

# Date of Preparation: March 19, 2014

# Owner:

Meridian Bioscience, Inc. 3471 River Hills Drive Cincinnati, Ohio 45244 USA Phone: (513) 271-3700 Fax: (513) 272-5213

# Contact:

Primary Contact:   
Michelle L. Smith   
Sr. Director, Regulatory Affairs & Design Assurance   
Secondary Contact:   
Susan D. Rolih   
Executive Vice President, Regulatory and Quality Systems

# Trade Name:

illumigene Pertussis DNA Amplification Assay illumigene Pertussis External Controls

# Common Name:

Respiratory Viral Panel Multiplex Nucleic Acid Assay

# Classification Name:

Bordetella Pertussis DNA Assay System (21 CFR 866.3980, Product Code OZZ)

# Predicate Device:

FilmArray® Respiratory Panel (RP), Catalog RFIT-ASY-001 K123620, K120267, K110764 and K103175,

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.Inspired Science. Trusted Solutions.</td><td rowspan=1 colspan=2>illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=1>Application Reference:</td><td rowspan=1 colspan=1>K133673</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Attachment Description:</td><td rowspan=1 colspan=1>Additional Information Request (January 13, 2014)510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Application Date:</td><td rowspan=1 colspan=1>March 19, 2014</td></tr></table>

# Device Description:

Teillumigene Molecular DagnosticTest Syste comprised  theilluiene® ertussisA Ampliatn Assay Test Kit, the illumigene® Pertussis External Control Kit and the illumipro- $1 0 ^ { n }$ Automated Isothermal Amplification and Detection System.

Th lizoeael oe orel pesu aharnl a eil eus completed using an illumigene Assay Control/Negative Control Reagent containing Control material, an im  T Dil aarl elut wil Sampl ufTe illAssyContl Reagn   elut heat-reaar Conol  avalabl oeal liineat-e. The heat-reate Specmen/Control sample  ddetohe illuigneTest Deviineral ls adde  e illumigene Test Device to prevent evaporation. DNA amplification occurs in the illumigene Test Device.

Th iheat cille erusss Test Devinaig pepa Samplan Contolal latn  r Wh ee located within the IS481 insertional element of the B. pertussis genome is amplified and magnesium pyrophosphate is generated. Magnesium pyrophosphate forms a precipitate in the reaction mixture.

The illumipro- $1 0$ monitors the absorbance characteristics of the reaction solutions at the assay Run Start (Signalinitial, S) and at the assay Run End $( \sin a \cos a , \sin a \cos a , \sin a )$ . The illumipro- $1 0 ^ { m }$ caiculates the ratio of the Run End (Signal final or $S _ { f } )$ reads with the Run Start (Signal Initial or $S _ { j }$ reads and compares the ratio to an established cu-f value.The illumipro-10 perfors this rati calculation to both the TT chamber and the COROL chamber.

Fixed cut-off values for the CONTROL chamber are used to determine validity. CONTROL chamber $S _ { f } : S _ { j }$ ratios less than $90 \%$ are considered valid and allow for reporting of TEST chamber results (POSITIVE, NEGATIVE). CONTROL chamber $S _ { f } : S _ { j }$ ratios greater than or equal to $90 \%$ are considered invalid. Results are reported as 'INVALID'; Test ense amplification is not inhibited, reagents are performing as intended and that sample processing was performed appropriately.

Fixed cut-off values for the TEST chamber are used to report sample results. TEST chamber $5 _ { f } = 5 _ { i }$ ratios less than $82 \%$ are reported as 'POSITIVE'; TEST chamber $S _ { f } : S _ { j }$ ratios greater than or equal to $82 \%$ are reported as 'NEGATIVE'. Numerical values are not reported.

The illumigene Pertusis External Control Kit contains a Positive Control Reagent. The illumigene Assay Control/Negative Control Reagent provided in the illumigene Pertussis it serves as he External Negative ConoReageExteal Contol eagent  provii heusr ndeteion  eagent detn, adver environmental r test conditions, or variance inoperator performance that may lead to test eos. Ex Cont   QualCn

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Truste Soluio</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

# Intended Use:

The illumigene® Pertussis DNA Amplification Assay, performed on the illumipro- $1 0 ^ { m }$ , is a qualitative in vitro iaostc t  etectin Borel perusumn asharngel a mplk from patients suspected of having respiratory tract infection attributable to Bordetell pertussis.

Thil uss ssil o-eelat Borella pertussis yargeting h Iisrtinal eement  the Bordetela pertussis eoe.The IS481 ln  f Borelloe BoretlaiicRes infecon with Bordetella pertussis, Bordetellaholmesii rBordetella bronchiseptica may ield positive test results in IS481 assys.B.holmesinfection may causecinical lnes similar to B. pertussis, and med ol ee al Wl clincally appropriate investigation(s) should be carried out in accordance with published guidelnes.

Neativ esuts or he illigee ertussis DA Amplfication Assy o ot preclue Boreella perusis inon an postiv result oottconetin wi he espratoy patogens. Resul m te illi  oul wtt t o ou e treatment or other patient management decisions.

i     tTv intended for point-of-care use.

# Predicate Device Comparison:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">DEVICEillumigene® Pertussis</td><td colspan="1" rowspan="1">PREDICATEFilmArray® Respiratory Panel (RP) SystemPackage Insert: RFIT-PRT-0011-02, May 2012</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Qualitative</td></tr><tr><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">Professional Use</td><td colspan="1" rowspan="1">Professional Use</td></tr><tr><td colspan="1" rowspan="1">Assay Target</td><td colspan="1" rowspan="1">Bordetella pertussis IS481 Insertional Element</td><td colspan="1" rowspan="1">Bordetella pertussis DNA, promoter region ofToxin gene</td></tr><tr><td colspan="1" rowspan="1">Specimen Types</td><td colspan="1" rowspan="1">Nasopharyngeal Swab</td><td colspan="1" rowspan="1">Nasopharyngeal Swab</td></tr><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Self contained and automated</td><td colspan="1" rowspan="1">Self contained and automated</td></tr><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplificatlon Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Soutions.</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">DEVICEillumigene® Pertussis</td><td colspan="1" rowspan="1">PREDICATEFilmArray® Respiratory Panel (RP) System</td></tr><tr><td colspan="1" rowspan="1">Test Format</td><td colspan="1" rowspan="1">DNA Amplification Assay; Loop-MediatedIsothermal Amplification (LAMP)</td><td colspan="1" rowspan="1">Multiplex PCR Amplification Assay</td></tr><tr><td colspan="1" rowspan="1">Reagents/Components</td><td colspan="1" rowspan="1">The illumigene Pertussis DNA AmplificationAssay Kit contains illumigene AssayControl/Negative Control, illumigene SampleBuffer, illumigene Pertussis Test Device andMineral Oil.External Positive Control materials areprovided separately in the illumigenePertussis External Control Kit. Theillumigene Assay Control/Negative Controlfunctions as the External Negative Control.The illumipro-10 is provided separately.</td><td colspan="1" rowspan="1">The FilmArray Respiratory Panel (RP) AssayKit contains FilmArray RP pouch, SampleBuffer, Hydration Solution, transfer pipettesand Sample Loading Syringes (with attachedcannula). The FilmArray Instrument withLoading Station is provided separately.</td></tr><tr><td colspan="1" rowspan="1">External Controls</td><td colspan="1" rowspan="1">External Positive Control for the illumigenePertussis Assay is provided in the illumigenePertussis External Control Kit.The External Positive Control Reagentcontains tris-buffered solution containingnon-infectious Plasmid DNA (B. pertussistarget DNA inserts) with azide (0.09%) as apreservative.The illumigene Assay Control/NegativeControl provided in the illumigene PertussisDNA Amplification Assay Kit functions as theExternal Negative Control.The Assay Control/Negative Control Reagentcontains tris-buffered solution containingformalin-treated E. coli harboring non-infectious Plasmid DNA (S. aureus insert) withazide (0.09%) as a preservative.</td><td colspan="1" rowspan="1">The FilmArray Respiratory Panel (RP) Assaydoes not require external controls. ExternalControls are not providedfor the FilmArrayRespiratory Panel (RP) Assay.</td></tr><tr><td colspan="1" rowspan="1">AmplificationTechnology and TargetSequence Detected</td><td colspan="1" rowspan="1">Assay performed with the illumipro-10™instrument, utilizes loop-mediated isothermalamplification (LAMP) technology for thedetection of 198 base pair (bp) sequence offound in the IS481 Insertional Element of thethe Bordetella pertussis genomeTheillumipro-10™ detects changes in reactionsolution absorbance by visible lighttransmission.</td><td colspan="1" rowspan="1">Assay performed with the FilmArrayInstrument, utilizes freeze-dried reagents toperform nucleic acid purification reversetranscription, and nested multiplex PCR withDNA melt analysis for the detection ofmultiple respiratory pathogens along with aspecific B. pertussis toxin DNA sequence..</td></tr><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences (continued)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>DEVICEillumigene® Pertussis</td><td rowspan=1 colspan=1>PREDICATEFilmArray® Respiratory Panel (RP) System</td></tr><tr><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>illumipro-10™ Automated IsothermalAmplification and Detection System</td><td rowspan=1 colspan=1>FilmArray Instrument</td></tr><tr><td rowspan=1 colspan=1>Reading Method</td><td rowspan=1 colspan=1>Visible Light Transmission</td><td rowspan=1 colspan=1>Fluorescence Emissions</td></tr><tr><td rowspan=1 colspan=1>Interpretation ofResults</td><td rowspan=1 colspan=1>Results of the illumigene Pertussis Assay areinterpreted by the illumipro-10 and reportedas INVALID, POSITIVE and NEGATIVE based onchange in light transmission of the reactionmixtures. EMPTY WELL is reported when anillumigene Test Device is not detected by theillumipro-10 or when questionable SignalInitial (Si) transmission is detected.</td><td rowspan=1 colspan=1>Results of the FilmArray Respiratory Panel(RP) Assay report are interpreted by theFilmArray Instrument for B. pertussis andreported as Detected, Not Detected orInvalid.</td></tr><tr><td rowspan=1 colspan=1>PerformanceCharacteristics</td><td rowspan=1 colspan=1>Prospective and Retrospective, All ComersPositive Percent Agreement (PPA):87.8 % [95% CI: 75.8 - 94.3%]Negative Percent Agreement (NPA):97.8% [95% CI: 96.3 - 98.7%]Retrospective Samples, SelectedPositive Percent Agreement (PPA):90.5 % [95% CI: 71.1 - 97.3%]Negative Percent Agreement (NPA):87.5% [95% CI: 64.0 - 96.5%]</td><td rowspan=1 colspan=1>Prospective SamplesPPA: 100.0% [95% CI:54.1 - 100%]NPA: 99.9% [95% CI: 99.5 - 100%]Retrospective SamplesPPA: 94.6% [95% CI: 85.1 - 98.9%]NPA: 96.5% [95% CI: 88.1 - 99.6%]</td></tr></table>

# NON-CLINICAL PERFORMANCE DATA

Analytical Performance:

# Precision/Reproducibility:

Blind coded panels of 10 samples were supplied to three independent laboratories. Samples were randomly sorted consisting of moderately positive $( n = 3 )$ , low positive $( n = 3 )$ , high negative $( n = 3 )$ and negative $( n = 1 )$ samples. Contrived moderately positive, low positive and high negative samples were prepared by inoculating simulated negative matrix (flocked nylon nasopharyngeal swabs inoculated with nasal wash) with Bordetella pertussis strain BAA-589, Tahoma I. A negative specimen containing no Bordetella pertussis was included in the study. Panel specimens were qualified for study use by replicate testing $( n = 2 0 )$ for each of three production lots of illumigene Pertussis.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

Testing was performed by at least two different operators at each site on the same day (intra-assay variability) for five days (inter-assay variability). Three lots of illumigene Pertussis and six illumipro-10 instruments were used in this study. Positive and Negative Controls were tested with each panel. The results are given in the table below:

<table><tr><td rowspan=2 colspan=1>Sample Type</td><td rowspan=2 colspan=2>Clinical Site 1PercentAgreement</td><td rowspan=2 colspan=2>Clinical Site 2PercentAgreement</td><td rowspan=2 colspan=2>Clinical Site 4PercentAgreement</td><td rowspan=1 colspan=6>Total</td></tr><tr><td rowspan=1 colspan=2>PercentAgreement</td><td rowspan=1 colspan=1>AverageS.:S</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>57.51</td><td rowspan=1 colspan=1>4.14</td><td rowspan=1 colspan=1>7.20%</td><td rowspan=1 colspan=1>95.9 - 100.0</td></tr><tr><td rowspan=1 colspan=1>Low Positive.</td><td rowspan=1 colspan=1>27/30</td><td rowspan=1 colspan=1>90.0&#x27;</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>86/90</td><td rowspan=1 colspan=1>95.6</td><td rowspan=1 colspan=1>58.16</td><td rowspan=1 colspan=1>10.02</td><td rowspan=1 colspan=1>17.23%</td><td rowspan=1 colspan=1>89.1 -98.3</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>26/30</td><td rowspan=1 colspan=1>86.7</td><td rowspan=1 colspan=1>23/30</td><td rowspan=1 colspan=1>76.7</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>78/90</td><td rowspan=1 colspan=1>86.7</td><td rowspan=1 colspan=1>96.19</td><td rowspan=1 colspan=1>11.47</td><td rowspan=1 colspan=1>11.92%</td><td rowspan=1 colspan=1>78.1 - 92.2</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>9/10</td><td rowspan=1 colspan=1>90.0</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>100.29</td><td rowspan=1 colspan=1>4.75</td><td rowspan=1 colspan=1>4.73%</td><td rowspan=1 colspan=1>83.3 - 99.4</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>56.83</td><td rowspan=1 colspan=1>4.83</td><td rowspan=1 colspan=1>8.50%</td><td rowspan=1 colspan=1>88.6 - 100.0</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.70</td><td rowspan=1 colspan=1>3.04</td><td rowspan=1 colspan=1>3.01%</td><td rowspan=1 colspan=1>88.6 - 100.0</td></tr></table>

# Detection limit:

Analytical Sensitivity studies were designed to determine, within $9 5 \%$ confidence intervals, the analytical limit of detection (LoD) of Bordetella pertussis. The LoD is the lowest number of colony-forming units (CFUs) per test aliquot that can be distinguished from negative samples with a high degree of probability $( 9 5 \% )$ . Bordetella pertussis strain BAA-589 was evaluated for analytical Limit of Detection. Culture confirmed stock concentrations were standardized and subsequently diluted serially into sterile saline. Dilutions ,were combined with simulated negative matrix (flocked nylon swabs inoculated with nasal wash screened negative for B. pertussis) prior to test; Meridian utilized a simulated negative matrix for all analytical studies.

Each ditution evaluated in the illumigene Pertussis assay used individually prepared replicates. Not all prepared dilutions were tested in the illumigene Pertussis assay; testing for select dilutions was discontinued when replicate testing did not meet criteria established for limit of detection (e.g. more than 1 negative replicate obtained). The lowest dilution producing positive results in at least 19 of 20 replicates was identified as the preliminary assay limit of detection. Once a preliminary LoD concentration was established, an additional 60 replicates were evaluated by two different technicians to confirm the final LoD concentration for each kit lot.

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.Inspired Science. Trusted Solutions.</td><td rowspan=1 colspan=2>illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=1>Application Reference:</td><td rowspan=1 colspan=1>K133673</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Attachment Description:</td><td rowspan=1 colspan=1>Additional Information Request (January 13, 2014)510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Application Date:</td><td rowspan=1 colspan=1>March 19, 2014</td></tr></table>

Testing was performed using three lots of illumigene Pertussis and six illumipro-10 instruments. External Positive and Negative Controls were tested daily. The Limit of Detection for the assay was reported as 1.48 CFU/Test or $3 2 6 5 \thinspace { \mathsf { C F U / m L } }$

The following B. pertussis strains were tested and produced positive reactions at the stated assay limit of detect of 1.48 CFU/Test $\{ 3 2 6 5 ~ \mathsf { C F U / m L } \}$ with illumigene Pertussis: ATCC 12743, ATCC 8478, ATCC 8467, ATCC 9797, ATCC 53894, ATCC 10380, ATCC 12742, and A639. The following B. pertussis strains were tested and produced positive reactions at 1.59 CFU/Test or 3500 CFU/mL) with illumigene Pertussis: ATCC 51445 and ATCC BAA-1335.

# Analytical specificity:

# Interference Testing:

Interfering substance testing was performed to assess the potential impact of nonmicrobial contaminants expected to be present in samples collected for Bordetella pertussis testing on illumigene Pertussis test results. Potentially interfering substances were tested with simulated negative and contrived positive (B. pertussis strain BAA-589) nasopharyngeal swab samples. Potentially interfering substances were added to eluted simulated negative and contrived positive swab samples in Tris EDTA at final concentrations of $0 . 1 \mathrm { m g / m L } , 1 \% \lor / \lor , 1 \% \mathrm { w / v } ,$ or greater and tested. Dilution Controls were prepared by adding a sterile saline solution in place of the potentially interfering substance.

The following biological substances, at the saturated solvent/diluents concentrations indicated do not interfere with the illumigene Pertussis test results: Mucin $( 1 \% \ w / \ v ) ,$ Human DNA $( 2 0 0 ~ \mathsf { n g } / \mu \iota )$ , Whole blood $( 1 \% w / v )$ .

The following chemical substances, at the saturated solvent/diluents concentrations indicated do not interfere with test results: Acetaminophen $( 1 0 m g / m L )$ ,Advil® [1buprofen $\{ 1 0 ~ \mathrm { m g / m L } \} ]$ , Afrin® Decongestant Nasal Spray [Oxymetazoline hydrochloride $( 0 . 0 0 0 5 \% \quad \mathsf { w } / \mathsf { v } ) ] .$ ,Albuterol Sulfate [Salbutamol sulfate $( 1 \% \quad \mathsf { w } / \mathsf { v } ) ] ,$ Aspirin (5 $m \geq ( m L )$ , Coricidin® HBP Cold/Flu tablets [Acetominophen (3.26 $m g / m L )$ . Chlorpheniramine maleate $( 0 . 0 2 ~ \mathrm { \ m g / m L } ) ] ,$ Diphenhydramine HCI $( 0 . 2 5 ~ \mathrm { \ m g / m L } )$ , Erythromycin $( 2 \% \ w / \ v )$ , Mupirocin $( 2 \% \ w / \ v )$ , Petroleum Jelly [White Petrolatum $( 1 \%$ EMPY $w / v ) ]$ , Robitussin® Cough+Chest Congestion DM Cough Syrup [Dextromethorphan HBr $( 0 . 1 m g / m L )$ , Guaifenesin $\{ 1 . 0 \ : \ : \mathrm { \ m g / m L } \} ,$ Suphedrine PE [Phenylephrine HCI (0.3 $m g / m L ) ] ,$ , Saline Nasal Spray [Sodium chloride $\{ 0 . 0 0 6 5 \% \ w / \mathsf { v } \} ] _ { i }$ Smokeless Tobacco (snuff) $( 1 \% w / v )$ ,Tobramycin $\{ 0 . 6 \mathrm { \ m g / m L } \}$ , Vicks® VaporRub® [Camphor $\{ 0 . 4 8 \% \ w / \mathsf { v } \}$ . Eucalyptus oil $( 0 . 1 2 \% \ \mathrm { w } / \nu )$ , Menthol $\left\{ 0 . 2 6 \% \ : \mathrm { w } / \mathrm { v } \right\} ]$ .

Ibuprofen $\mathrm { \Omega } ^ { \mathrm { } } 1 0 \mathrm { \ m g / m L } )$ produced invalid results $( 3 / 6$ replicates) during original testing of contrived $B$ pertussis specimens. All repeat testing produced positive results (10/10 replicates). As the original results were not confirmed, Ibuprofen $( 1 0 m g / m L )$ is not considered an interfering substance.

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.Inspired Science. Trusted Solutions.</td><td rowspan=1 colspan=2>illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=1>Application Reference:</td><td rowspan=1 colspan=1>K133673</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Attachment Description:</td><td rowspan=1 colspan=1>Additional Information Request (January 13. 2014)510(k) $ummary</td></tr><tr><td rowspan=1 colspan=1>Application Date:</td><td rowspan=1 colspan=1>March 19, 2014</td></tr></table>

Aspirin was found to interfere with illumigene Pertussis testing at concentrations above $5 \ m g / \ m L$ .

# Cross-Reactivity Study:

Potentially cross-reacting microorganisms expected to be present in nasopharyngeal swab specimens were added to negative and contrived positive samples. Negative samples were prepared with flocked nylon nasopharyngeal swabs inoculated with confirmed negative nasal wash. The contrived positive sample was prepared by spiking confirmed negative sample matrix (flocked nylon nasopharyngeal swabs inoculated with nasal wash) with Bordetella pertussis strain BAA-589, at concentrations at or around the determined limit of detection. Dilution Controls were prepared by adding a sterile saline solution in place of the potentially cross-reactive organisms. Each inoculated sample was tested in triplicate.

Potentially cross-reactive microorganisms were at minimum concentrations of $1 . 0 \times { 1 0 } ^ { 6 }$ $C F U / \mathsf { m L }$ for bacteria/fungi or concentrations greater than $1 . 0 \times 1 0 ^ { 5 } \tau ( \mathrm { | } \mathsf { D } _ { 5 0 } / \mathrm { m L }$ for viruses.

None of the following organisms reacted with illumigene Pertussis:

Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter Iwoffii, Actinomyces odontolyticus, Arcanobacterium haemolyticum, Bacillus subtilis, Bacteroides fragilis, Bordetella avium, Bordetella hinzii, Bordetella parapertussis, Bordetella petrii, Bordetella trematum, Burkholderia cepacia, Candida albicans, Candida glabrata, Chlamydia pneumoniae, Chlamydia trachomatis, Citrobacter freundii, Clostridium difficile, Corynebacterium diphtheriae, Corynebacterium pseudodiphtheriticum, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli (ESBL), Fusobacterium nucleatum, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella oxytoca, Klebsiella pneumoniae (KPC), Lactobacillus acidophilus, Lactobacillus plantarum, Legionella jordanis, Legionella longbeachae, Legionella micdadei, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma pneumoniae, Neisseria cinerea, Neisseria elongata, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Peptostreptococcus anaerobius, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas fluorescens, Serratia liquefaciens, Staphylococcus aureus, Staphylococcus epidermidis, Stenotrophomonas maltophilia, Streptococcus anginosus (Group F), Streptococcus bovis (Group D), Streptococcus canis (Group G), Streptococcus dysgalactiae ssp. dysgalactiae, Streptococcus dysgalactiae ssp. equisimilis Streptococcus intermedius, Streptococcus mitis, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus suis, Ureaplasma urealyticum, Adenovirus,

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

Coronavirus, Coxsackievirus, Cytomegalovirus, Epstein Barr Virus, Herpes Simplex Virus 1, Herpes Simplex Virus 2, Human Metapneumovirus, Influenza A, Influenza B, Measles virus, Mumps virus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Respiratory syncytial virus A, Respiratory syncytial virus B, Rhinovirus.

Bordetella holmesii and Bordetella bronchiseptica also contain the IS481 insertional element. Bordetella bronchiseptica ATCC® Strain 4617 and Bordetella holmesii were tested at $1 . 0 \times 1 0 ^ { 6 } ( F U / m L$ and found  c wi e illen ussis ssy.

Unexpected results were observed during original testing of specimens containing B. hinzii, H. parainfluenzae and M. genitalium. One of three negative sample replicates containing 8. hinzii produced a false-positive result that was not confirmed with further testing (20/20 replicates). Three of three negative sample replicates containing H. parainfluenzae produced false-positive results that were not confirmed with further testing (20/20 replicates). Three of three B. pertussis positive sample replicates produced invalid results that were not confirmed with further testing (10/10 replicates). Three of three negative sample replicates containing M. genitalium produced invalid results that were not confirmed with further testing (10/10 replicates). As repeat testing using a heightened number of replicates did not confirm original results, B. hinzii, H. parainfluenzae and M. genitalium are not considered cross-reactive or interferents in illumigene Pertussis testing.

# Assay cut-off:

The illumigene Pertussis assay is manufactured with fixed cut-off values. The product is designed around a pre-selected cut-off value and amplification reagent concentrations are optimized to ensure appropriate reactions are obtained. Development optimization includes evaluation of characterized positive and negative clinical specimens. Amplification reagent concentrations are adjusted during design as needed to ensure illumigene results are aligned with clinical specimen reported results.

Cut-off values applied in the following manner:

The illumipro- $1 0 ^ { m }$ calculates the ratio of the Run End (Signal final or S) reads with the Run Start (Signal Initial or S:) reads and compares the ratio to an established cut-off value. The illumipro-10 performs this ratio calculation to both the TEST chamber and the CONTROL chamber.   
Fixed cut-off values for the CONTROl chamber are used to determine validity. CONTROL chamber $S _ { f } : S _ { j }$ ratios less than $90 \%$ are considered valid and allow for reporting of TEST chamber results (POSITIVE, NEGATIVE). CONTROL chamber $S _ { f } : S _ { j }$ ratios greater than or equal to $90 \%$ are considered invalid. Results are reported as 'INVALID'; Test chamber results are not reported. More stringent cut-off criteria are applied to the Control chamber reaction to ensure amplification is not inhibited, reagents are performing as intended and that sample processing was performed appropriately.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

Fixed cut-off values for the TEsT chamber are used to report sample results. TEST chamber $S _ { f } : S _ { i }$ ratios less than $82 \%$ are reported as 'POSITIVE'; TEST chamber $S _ { f } : S _ { i }$ ratios greater than or equal to $82 \%$ are reported as 'NEGATIVE'. Numerical values are not reported.

# CLINICAL PERFORMANCE DATA:

# Clinical Studies:

# Clinical Performance:

Clinical trials for the illumigene Pertussis DNA Amplification Assay, including the illumipro-10 Automated Isothermal amplification and detection system, were conducted from December 2012 to July 2013. A total of 729 qualified nasopharyngeal (NP) swab specimens collected from patients suspected of having Bordetella pertussis infection were evaluated with the test. All specimens were leftover and de-identified.

Performance characteristics of the assay were determined by comparison to a Composite Comparator Reference Method that included two manufacturer validated, real-time PCR Assays (PCR1 and PCR2) followed by bi-directional sequencing. Both comparator PCR assays targeted unique sequences within the IS481 insertional element; neither of the comparator target sequences overlaps with the illumigene Pertussis assay target sequence. Specimens producing positive Bordetella pertussis results from either comparator PCR assay were sent for bi-directional sequencing. Only samples that matched sequences within the Bordetella pertussis genome with pre-defined quality scores (PHRED20 and E-values) were considered true positives. Samples were considered negative when neither comparator PCR assay returned positive Bordetella pertussis results.

The clinical study population included retrospective and prospective specimens. A total of 508 $( 6 9 . 7 \% )$ prospective and 221 $( 3 0 . 3 \% )$ retrospective specimens were tested and included in final performance calculations. The retrospective sample population included non-selected specimens (all comers) and selected specimens. Overall performance characteristics of illumigene Pertussis Assay are summarized in Table 1.

<table><tr><td rowspan=4 colspan=3>MeridianBioscience, Inc.d ScienTru Sol</td><td rowspan=1 colspan=3>illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=2>Application Reference:</td><td rowspan=1 colspan=1>K133673</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Attachment Description:</td><td rowspan=1 colspan=1>Additional Information Request (January 13, 2014)510(k) Summary</td></tr><tr><td rowspan=1 colspan=2>Application Date:</td><td rowspan=1 colspan=1>March 19, 2014</td></tr></table>

Table 1. illumigene Assay Performance   

<table><tr><td rowspan=2 colspan=1>SpecimenDescription</td><td rowspan=1 colspan=3>Positive Specimens</td><td rowspan=1 colspan=3>Negative Specimens</td><td rowspan=2 colspan=1>InvalidResults</td></tr><tr><td rowspan=1 colspan=1>illumigenevs.Comparator</td><td rowspan=1 colspan=1>PPA^{</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigenevs.Comparator</td><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=8>Composite Method Comparator, All Comers</td></tr><tr><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>39/45</td><td rowspan=1 colspan=1>86.7%</td><td rowspan=1 colspan=1>73.8 - 93.7%</td><td rowspan=1 colspan=1>447/459</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>95.5 - 98.5%</td><td rowspan=1 colspan=1>2 (13)</td></tr><tr><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>51.0 - 100.0%</td><td rowspan=1 colspan=1>176/178</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>96.0 - 99.7%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total:</td><td rowspan=1 colspan=1>43/49</td><td rowspan=1 colspan=1>87.8%</td><td rowspan=1 colspan=1>75.8 -94.3%</td><td rowspan=1 colspan=1>623/637</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>96.3  98.7%</td><td rowspan=1 colspan=1>2(13)</td></tr><tr><td rowspan=1 colspan=8>Composite Method Comparator, Selected Specimens</td></tr><tr><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>19/21</td><td rowspan=1 colspan=1>90.5%</td><td rowspan=1 colspan=1>71.1-97.3%</td><td rowspan=1 colspan=1>14/16</td><td rowspan=1 colspan=1>87.5%</td><td rowspan=1 colspan=1>64.0 - 96.5%</td><td rowspan=1 colspan=1>0</td></tr></table>

i t comparator PCR/Sequencing assays.

False-negative illumigene results were individually evaluated at the conclusion of clinical testing. The Cycle threshold (Ct) values produced during comparator assay testing were above 35 for one or both PCR/Bi-directional sequencing assays for six of the eight specimens evaluated. High Ct values in PCR assays may indicate that low levels of DNA are present. False-negative illumigene results and corresponding Composite Comparator data are shown in Table 2.

Table 2. False-Negative illumigene Specimens, Comparator Assay Results   

<table><tr><td rowspan=2 colspan=1>SpecimenDesignation</td><td rowspan=2 colspan=1>SpecimenStatus</td><td rowspan=1 colspan=2>PCR1</td><td rowspan=1 colspan=2>PCR2</td></tr><tr><td rowspan=1 colspan=1>Ct Value</td><td rowspan=1 colspan=1>Bi-DirectionalSequencingResult</td><td rowspan=1 colspan=1>Ct Value</td><td rowspan=1 colspan=1>Bi-DirectionalSequencingResult</td></tr><tr><td rowspan=1 colspan=1>1-19</td><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>34.90</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>33.85</td><td rowspan=1 colspan=1>*</td></tr><tr><td rowspan=1 colspan=1>1-29</td><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>37.69</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>1-259</td><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>34.07</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>35.09</td><td rowspan=1 colspan=1>*</td></tr><tr><td rowspan=1 colspan=1>1-269</td><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>35.72</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>1-275</td><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>39.13</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>3-33</td><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>39.28</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>35.80</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>4-710</td><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>36.87</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>36.06</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>4-712</td><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>37.44</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>38.41</td><td rowspan=1 colspan=1>+</td></tr></table>

Four independent clinical test sites located in the Midwestern, Northern, Southern, and Eastern regions of the United States participated in the device evaluation All samples included in the study were submitted to the testing laboratory by an ordering physician for Bordetella pertussis testing and were presumed from symptomatic patients. No restrictions were placed on age, gender, medications or known pharmaceutical therapies.

<table><tr><td rowspan=4 colspan=3>MeridianBioscience, Inc.Inspired Science. Trusted Solutions.</td><td rowspan=1 colspan=3>illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=2>Application Reference:</td><td rowspan=1 colspan=1>K133673</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td rowspan=1 colspan=1>Attachment Description:</td><td rowspan=1 colspan=1>Additional Information Request (January 13, 2014)510(k) Summary</td></tr><tr><td rowspan=1 colspan=2>Application Date:</td><td rowspan=1 colspan=1>March 19, 2014</td></tr></table>

Clinical studies were conducted with multiple nasopharyngeal swab and sample elution buffer types. Sample buffers tested during clinical studies included $0 . 8 5 \ \%$ Saline $[ n = 3 0$ or $4 . 1 \% )$ , Tris EDTA $: n = 8$ or $\pm . 1 \% \AA ]$ and Molecular Grade Water $( n = 6 8 7$ or $9 4 . 2 \% \cdot )$ . All sample buffers were used in $0 . 5 ~ \mathsf { m L }$ volumes. Analytical studies were performed with $0 . 8 5 \%$ Saline, Tris EDTA, Phosphate Buffered Saline (PBS) and Molecular Grade Water. Analytical studies established equivalence between all sample elution buffer types.

Clinical performance data was evaluated by patient age and gender. Age information was known for 723 $( 9 9 . 2 \% )$ of the patients from whom samples were tested. Patient age ranged from 1 month to 88 years. Thirty-eight $( 5 . 2 \% )$ patients were less than 1 year of age; 13 $( 1 . 8 \% )$ were between 1 and 2 years old; 296 $( 4 0 . 6 \% )$ were between 2 and up to 12 years, 157 $( 2 1 . 5 \% )$ were between 12 and up to 21 years, 190 $( 2 6 . 0 \% )$ were above 21 but below 65 years, and the remaining 29 $( 4 . 0 \% )$ patients were above 65 years of age. The study population included 413 $( 5 6 . 7 \% )$ female and 308 $( 4 2 . 2 \% )$ male patients. Gender was unknown for 8 $( 1 / 1 \% )$ patients included in the study. There is no expectation that the illumigene Pertussis assay performance characteristics are influenced by patient gender.

Performance data by Clinical Test Site, analyzed based on the Composite Reference Method, is shown in Table 3. Statistical analysis of Site performance data was performed with no significant difference among Sites identified.

b . llumigene Pertussis Assay Performance b Clinical Test Site, ComposieReference Method (RM)   

<table><tr><td rowspan=2 colspan=1>Specimen Description</td><td rowspan=1 colspan=3>Positive Specimens</td><td rowspan=1 colspan=3>Negative Specimens</td><td rowspan=2 colspan=1>InvalidResults</td></tr><tr><td rowspan=1 colspan=1>illumigenevs.Comparator</td><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigenevs.Comparator</td><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=8>Composite Method Comparator, All Comers</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>35/40</td><td rowspan=1 colspan=1>87.5%</td><td rowspan=1 colspan=1>73.9 - 94.5%</td><td rowspan=1 colspan=1>440/450</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>96.0 - 98.8%</td><td rowspan=1 colspan=1>2 (13)</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>51.0 - 100.0%</td><td rowspan=1 colspan=1>67/69</td><td rowspan=1 colspan=1>97.1%</td><td rowspan=1 colspan=1>90.0 - 99.2%</td><td rowspan=1 colspan=1>0 (2)</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>0/1</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0 - 79.3%</td><td rowspan=1 colspan=1>7/7</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>64.6 - 100.0%</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>51.0 - 100.0%</td><td rowspan=1 colspan=1>109/111</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=1>93.7 - 99.5%</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=8>Composite Method Comparator, Selected Specimens</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>15/15</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>79.6 - 100.0%</td><td rowspan=1 colspan=1>6/8</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>40.9 - 92.9%</td><td rowspan=1 colspan=1>0(0)</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>4/6</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>30.0 - 90.3%</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>.100.0%</td><td rowspan=1 colspan=1>67.6 - 100.0%</td><td rowspan=1 colspan=1>0 (0)</td></tr></table>

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Pertussis DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>K133673</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>Additional Information Request (January 13, 2014) 510(k) Summary</td></tr><tr><td>Application Date:</td><td>March 19, 2014</td></tr></table>

# Expected values/Reference Range:

Overall incidence of . pertussis as detected by the illumigene Pertussis Assay in prospectively and retrospectively collected, non-selected specimens (all comers) during the period of this study was $8 . 2 \%$ (57/692).

# CONCLUSIONS

The illumigene® Pertussis DNA amplification assay, performed on the illumipro- ${ \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla }$ , can be used to detect Boetelaperussi uan nasharyngl wataie fro patent speehavie infection attributable to Bordetella pertussis.

March 25, 2014

MERIDIAN BIOSCIENCE, INC.   
MICHELLE SMITH   
SR. DIRECTOR REGULATORY AFFAIRS AND DESIGN ASSURANCE 3471 RIVER HILLS DRIVE   
CINCINNATI, OH 45244

Re: K133673 Trade/Device Name: illumigene Pertussis DNA Amplification Assay Regulation Number: 21 CFR 866.3980 Regulation Name: Respiratory Viral Panel Multiplex Nucleic Acid Assay Regulatory Class: I1 Product Code: OZZ Dated: March 13, 2014 Received: March 19, 2014

Dear Ms. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactiment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class Il (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Acl or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systeims (QS) regulation (21 CFR Part 820); and if applicable, the clectronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2Ms. Smith

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Sally Hojvat, M.Sc., Ph.D   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Enclosure

<table><tr><td></td><td>DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use</td><td>Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page.</td></tr><tr><td colspan="3">510(k) Number (if known) K133673 </td></tr><tr><td colspan="3">Device Name illumigene® Pertussis DNA Amplification Assay</td></tr></table>

Indications for Use (Describe)

The illumigene® Pertussis DNA Amplification Assay, performed on the illumipro ${ \mathfrak { l o } } ^ { m }$ , is a qualitative in vitro n oela  arl   ak patients suspected of having respiratory tract infection attributable to Bordetella pertussis.

The ilie erussis ssyutiizs loo-ediat stermal A pliicatin P) tecnolgy et Bordtella pertussis b targeting the I48insrtinalment of the Bordetela pertussis e.The IS481 Blao olc i o l facor sgst that peruss may ot be the cus  respatoyincin, occaly pe investigation(s) should be carried out in accordance with published guidelines.

n a psiv eul o ot ut on w spoy patesu o e illn oela eun l patient management decisions.

for point-of-care use.

# This section applies only to requirements of the Paperwork Reduction Act of 1995.

\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burdn timeorhicollection noation sated veragours per sponsenc time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OM8 number."